| Generalized social anxiety disorder (SAD) | Randomized, double-blind, controlled trial | Sample: a total of 24 never-treated subjects with generalized SAD and 12 healthy control subjects | SAD patients were randomly assigned to two groups with 12 subjects each to receive CBD (600 mg) or placebo 1 hour and half an hour before the test
Healthy controls (n. 12) did not receive any medication | Simulation public speaking test (SPST)
Subjective ratings on VAMS and negative self-statement scale, and physiological measures (blood pressure, heart rate, and skin conductance) were measured at six different time points during the SPST | Pretreatment with CBD significantly reduced anxiety, cognitive impairment, and discomfort in speech performance and significantly decreased alert in anticipatory speech | Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naıve social phobia patients; Bergamaschi et al. [37] |
| Generalized social anxiety disorder (SAD) | Randomized, double-blind, placebo-controlled, crossover study | Sample: 10 treatment-naıve patients with SAD aging 20–33 years (mean age 24.2 years; SD 3.7) | Acute oral dose of CBD (400 mg) or placebo | Brief Social Phobia Scale (BSPS) and Social Phobia Inventory (SPIN) regional cerebral blood flow (rCBF) at rest was measured twice using (99 m) Tc-ECD SPECT | Reduction anxiety in SAD patients associated with reduced ECD uptake in the left parahippocampal gyrus, hippocampus, and inferior temporal gyrus, and increased ECD uptake in the right posterior cingulate gyrus | Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report; Crippa et al. [38] |
